(Q36670887)

15 August 2017

1 reference

title

Present and future therapy for hepatitis C virus (English)

1 reference

15 August 2017

1 reference

3

Michael P Manns

1 reference

15 August 2017

1

Markus Cornberg

1 reference

15 August 2017

Katja Deterding

2

1 reference

15 August 2017

publication date

1 October 2006

1 reference

Expert Review of Anti-infective Therapy

15 August 2017

published in

1 reference

15 August 2017

volume

4

1 reference

15 August 2017

issue

5

1 reference

15 August 2017

page(s)

781-793

1 reference

Global epidemiology of hepatitis C virus infection

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.781

Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.781

Hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.781

Hepatitis C: the clinical spectrum of disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.781

Autoimmunity and extrahepatic manifestations in hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.781

Projecting future complications of chronic hepatitis C in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.781

Treatment of chronic hepatitis C with PEGylated interferon and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.781

The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.781

Hepatitis C virus infection in sexually active homosexual men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.781

Immunology of hepatitis B virus and hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.781

Prospects for a vaccine against the hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.781

High-dose interferon-alpha2b treatment prevents chronicity in acute hepatitis C: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.781

Treatment of acute hepatitis C with interferon alfa-2b

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.781

Efficacy of a 24-week course of PEG-interferon alpha-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.781

Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.781

Pegylated interferon alpha therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.781

Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.781

Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.781

[Diagnosis, progression and therapy of hepatitis C virus infection as well as viral infection in children and adolescents--results of an evidenced based consensus conference of the German Society for Alimentary Metabolic Disorders and and in coopera

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.781

Treatment of chronic hepatitis C in active drug users.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.781

High rate of spontaneous clearance of acute hepatitis C virus genotype 3 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.781

Dominant influence of an HLA-B27 restricted CD8+ T cell response in mediating HCV clearance and evolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.781

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.781

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.781

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.781

Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.781

Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.781

Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.781

Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.781

Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.781

Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.781

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.781

Paroxetine for the prevention of depression induced by high-dose interferon alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.781

Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.781

Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.781

Mechanism of action of ribavirin in the combination treatment of chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.781

Mutagenic effects of ribavirin in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.781

The structure of inosine 5'-monophosphate dehydrogenase and the design of novel inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.781

Mycophenolate mofetil in combination with recombinant interferon alfa-2a in interferon-nonresponder patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.781

Use of granulocyte macrophage colony stimulating factor alone or in combination with interferon-alpha-2b for treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.781

Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.781

Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.781

Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.781

The Caspase Inhibitor IDN-6556 Attenuates Hepatic Injury and Fibrosis in the Bile Duct Ligated Mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.781

Apoptosis: the nexus of liver injury and fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.781

Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.781

Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.781

Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.781

Production of infectious hepatitis C virus in tissue culture from a cloned viral genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.781

The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.781

Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.781

Interferon alfacon-1 and ribavirin versus interferon alpha-2b and ribavirin in the treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.781

Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: a randomized open-label pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.781

A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.781

Treating hepatitis C infection in liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.781

What determines the natural history of recurrent hepatitis C after liver transplantation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.781

Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.781

Prophylactic and preemptive therapies for hepatitis C virus-infected patients undergoing liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.781

Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.781

Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.781

Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.781

Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.781

Meta-analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.781

Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.781

21 January 2018

Identifiers

DOI

10.1586/14787210.4.5.781

1 reference

15 August 2017

1 reference